Therapy News and Research

RSS

Truth on postmenopausal hormone therapy and coronary disease

With each new publication of coronary artery disease (CAD) data from the Women's Health Initiative (WHI) study, the inevitable reaction is ,Why on earth did the WHI investigators claim in 2002-2004 that postmenopausal hormone therapy has deleterious effects on the risk for CAD, when, from the beginning, they were aware of the importance of the age factor in this clinical scenario".

23 Jun 2007

FDA approves Differin (adapalene) gel, 0.3% for acne

Galderma Laboratories, L.P., has announced that the U.S. Food and Drug Administration (FDA) has approved Differin (adapalene) Gel, 0.3%, a new, higher concentration formulation of Differin (adapalene) 0.1%, a topical retinoid indicated for the treatment of acne.

23 Jun 2007

Genzyme files for FDA approval of single-treatment Synvisc-One

Genzyme Corp. has announced that it has filed with the U.S. Food and Drug Administration (FDA) for approval of Synvisc-One, the single treatment of Synvisc (hylan G-F 20) that provides up to six months of pain relief from osteoarthritis (OA) of the knee.

23 Jun 2007

Estrogen use lowered one risk factor for heart disease among some younger postmenopausal women

A follow-up study to the federally funded Women's Health Initiative should help allay one concern in a subset of women in their 50s who are considering taking estrogen to relieve hot flashes.

23 Jun 2007

Drug warning prompts treatment changes for those infected with hepatitis B and HIV

Cross-resistance alarms raised earlier this year by Johns Hopkins researchers about a widely used antiviral therapy for hepatitis B liver infections have prompted swift treatment revisions by the drug's maker and governmental agencies.

23 Jun 2007

Estrogen HRT can limit plaque accumulation in arteries

Estrogen can limit significantly the accumulation of plaque in the arteries of women in their 50s, according to a study published on Thursday in the New England Journal of Medicine, the Milwaukee Journal Sentinel reports (Newson, Milwaukee Journal Sentinel, 6/20).

22 Jun 2007

Stem cells to repair damaged heart muscle

In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery.

22 Jun 2007

HRT not such a bad idea after all!

Older women struggling to cope with the symptoms of the menopause will be reassured by the latest research into hormone replacement therapy (HRT).

21 Jun 2007

Myeloma cancer drug gets the green light from the EU

The European Union has given the green light to a drug which doubles the survival rates for people with myeloma.

21 Jun 2007

New treatments for migraines and chronic headaches

Twelve percent of the population, three quarters of them women, suffer at least occasionally from migraines and about 5 percent from chronic headaches.

20 Jun 2007

Costs of disorders of the brain in Europe

In 2004 there were about 46 million cases of neurological diseases such as epilepsy, migraines, multiple sclerosis, Parkinson's disease and stroke among the 466 million inhabitants of the EU (excluding the two new members Romania and Bulgaria, but including the non-members Iceland, Norway and Switzerland).

20 Jun 2007

More effective treatment for malaria control during pregnancy in Africa

A review of previous studies indicates that two doses of a malaria preventive therapy during pregnancy provides substantial benefit to HIV-negative women in Africa, with more frequent dosing apparently necessary for HIV-positive women, according to an article in the June 20 issue of JAMA.

20 Jun 2007

Scientists develop unique “switch” that can control the activity of any protein

Our bodies could not maintain their existence without thousands of proteins performing myriad vital tasks within cells. Since malfunctioning proteins can cause disease, the study of protein structure and function can lead to the development of drugs and treatments for numerous disorders.

20 Jun 2007

New molecular mechanism discovered that may 'spontaneously' cause liver cancer

Adding more good news to last week's announcement that Nexavar (sorafenib) may be the first effective treatment for advanced liver cancer, researchers at the Lombardi Comprehensive Cancer Center at Georgetown University have uncovered a new molecular mechanism that may 'spontaneously' cause liver cancer.

20 Jun 2007

Microfluidic chip for cancer diagnosis

For the first time an important diagnostic test for cancer has been miniaturized and automated onto a microfluidic chip by a team of University of Alberta researchers in Edmonton, Canada.

20 Jun 2007

Intraoperative radiation therapy for breast cancer

Princess Margaret Hospital (PMH) breast cancer specialists are using a new way to treat patients by delivering a one-time dose of radiation during surgery.

20 Jun 2007

Orphan drug status granted to Immtech for malaria treatment pafuramidine

Immtech Pharmaceuticals, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for pafuramidine (DB289) for the treatment of malaria.

19 Jun 2007

New genome sequencing technology quickly detects rare viral mutations

Rare, previously undetectable drug-resistant forms of HIV have been identified by Yale School of Medicine researcher Michael Kozal, M.D., using an innovative genome sequencing technology that quickly detects rare viral mutations.

19 Jun 2007

Remicade helps those with ankylosing spondylitis

Data presented at the European League Against Rheumatism (EULAR) Annual European Congress of Rheumatology showed that patients with ankylosing spondylitis (AS) who received REMICADE, (infliximab) over two years experienced significant improvement in spinal mobility.

19 Jun 2007

Extended exposure to the psoriasis medication etanercept reduces psoriasis severity without increased adverse events

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology.

19 Jun 2007